NCT03190915 2026-03-19
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT02407405 2026-03-05
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03962543 2025-08-07
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
NCT02964884 2025-06-24
Interventions for Reading Disabilities in NF1
Vanderbilt University
Phase 2 Active not recruiting
NCT04481048 2024-10-09
DoDNAC
Children's Hospital Medical Center, Cincinnati
Phase 2 Active not recruiting
NCT03741101 2024-04-11
plexifpc
Region Skane
Phase 2 Active not recruiting
NCT03363217 2023-11-27
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
St. Justine's Hospital
Phase 2 Active not recruiting